
Work Here?
EMED Technologies manufactures medical devices and drug delivery systems specifically for subcutaneous infusion of biologics and specialty drugs. Its products, such as the SCIg60 system and VersaPump, use mechanical syringe pumps and variable flow rate controllers to allow patients to safely administer medication at home. Unlike many competitors, the company provides a complete end-to-end B2B solution that includes device design, AI-monitored manufacturing, and final packaging for pharmaceutical partners. The company's goal is to increase patient independence and quality of care by providing accessible, home-based infusion platforms across global markets.
Industries
Industrial & Manufacturing
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$8M
Headquarters
California
Founded
1987
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$8M
Above
Industry Average
Funded Over
1 Rounds
Professional Development Budget
/PRNewswire/ -- Today, EMED Technologies, a global leader in drug delivery and innovative infusion therapy devices announced that its subsidiary closed a...
MIAMI, Sept. 30, 2025 /PRNewswire/ - eMed Population Health, Inc. today announced the appointment of Dr. Dyan Hes as Chief Medical Officer.
MIAMI, Sept. 8, 2025 /PRNewswire/ - eMed Population Health, Inc. today announced the appointment of Amy Elkins as Chief Operating Officer.
Aon invests in eMed to expand GLP-1 weight management programs
Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity managementMIAMI, May 5, 2025 /PRNewswire/ -- eMed®, the leading Population Health technology platform in remote chronic care management and 24/7/365 live care, today announced an industry-changing collaboration with leading global professional services firm, Aon , to provide GLP-1 obesity management services for the company's U.S. employees.This collaboration builds off the momentum from Aon's recently released findings showing a seven percentage point reduction in the growth of medical spend in the second year of GLP-1 therapy, and a 44 percent reduction in risk of hospitalizations caused by major adverse cardiovascular events with adherent GLP-1 utilization. Both eMed and Aon are committed to improving population health by accessible, personalized, and effective healthcare solutions that support better health outcomes and address critical issues such as obesity, diabetes, and related comorbidities."We are thrilled to collaborate with Aon to bring our cutting-edge platform to their employees," said Dr. Patrice Harris, CEO of eMed. "Our platform is a science-based, all-in-one solution proven to deliver superior health outcomes for participants, while enabling employers to manage their spend on GLP-1s. Together with Aon, we're not just offering access to GLP-1s; we're ensuring they are used effectively to improve long-term employee health outcomes as demonstrated by Aon's groundbreaking analysis.""Our findings show that GLP-1s, when combined with holistic support like nutrition, exercise and mental health resources, can deliver lasting health improvements
Find jobs on Simplify and start your career today
Industries
Industrial & Manufacturing
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$8M
Headquarters
California
Founded
1987
Find jobs on Simplify and start your career today